FDA Approves METFORMIN HYDROCHLORIDE — Lifsa Drugs, LLC

The FDA has granted approval for Lifsa Drugs, LLC’s Abbreviated New Drug Application for Metformin Hydrochloride, potentially expanding generic supply options for diabetes patients without conflicting with brand patents. This clearance allows Lifsa to compete within the oral antidiabetic market, further reinforcing the availability and lower cost of first-line glucose-lowering therapies.